Femasys Inc. (FEMY)
NASDAQ: FEMYHealthcareMedical Instruments & SuppliesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
FEMY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $17.13M
- EPS (TTM)
- -$3.28
- Dividend yield
- None
- 52-week range
- 1.94 – 22.20
- Day range
- 1.94 – 2.11
- Volume / Avg
- 62.66K / 722.09K
- Beta
- —
- Shares outstanding
- 8.38M
52-week range
FEMY stock today
On Oct 8, FEMY ended the session at $2.05, adding $0.045 (2.25%), versus the S&P 500's 0.47% decline. Trading was light, with 62.66K shares changing hands, about 9% of the average daily volume. Shares are 90.8% below their 52-week high of $22.20, set on Nov 10, 2025 and 5.4% above the 52-week low of $1.94, near the bottom of the past year's range.
FEMY is down 82.2% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 82.9%. Femasys has posted a net loss over the last twelve months (EPS of -$3.28), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Femasys
Company profileFemasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- CEO
- Ms. Kathy Lee-Sepsick M.B.A.
- Headquarters
- Suwanee, GA
- Employees
- 51
- IPO year
- 2021
- Website
- femasys.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$14.33+600.73%
- Strong buy 2
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
FEMY news
All FEMY newsFemasys peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BNGOBionano Genomics Inc. | 1.46 | 0.00% | $17.19M | vs FEMY |
| RVPRetractable Technologies Inc. | 0.662 | -4.17% | $19.82M | vs FEMY |
| CUPRCuprina Holdings (Cayman) Limited Class A | 1.90 | -4.52% | $13.31M | vs FEMY |
| RGNTRegentis Biomaterials Ltd. | 1.70 | +4.29% | $11.94M | vs FEMY |
| LUCYInnovative Eyewear Inc. | 0.8967 | -1.68% | $7.81M | vs FEMY |
| MLSSMilestone Scientific Inc. | 0.36 | -2.70% | $32.62M | vs FEMY |
| NXGLNexGel Inc | 0.15 | -15.35% | $1.46M | vs FEMY |
| NEPHNephros Inc. | 3.29 | +2.81% | $35.73M | vs FEMY |
Indexes, lists and sector
Appears in lists
Femasys stock FAQ
What is Femasys's stock price today?
FEMY last traded at $2.05 as of Oct 8, 4:00 PM EDT, up 2.25% on the day. Prices are delayed at least 15 minutes.
Does Femasys pay a dividend?
No. Femasys does not currently pay a regular cash dividend.
Who is Femasys's CEO?
Ms. Kathy Lee-Sepsick M.B.A. is the chief executive officer of Femasys Inc., which has about 51 employees.
Has FEMY ever split its stock?
Yes. The most recent FEMY stock split was a 1-for-20 split on Jun 8, 2026.
What is the FEMY 52-week high?
The 52-week high for FEMY is $22.20 and the 52-week low is $1.94. The stock is currently 90.8% below its high.